International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, Mohakhali, 1212, Bangladesh
NCT Number: NCT03870243
Principal Investigator: Mohammod Jobayer Chisti
Research Protocol Title: Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial
Proposed start date: 1st July 2018, Estimated end date: 31st December 2022
Background: Feasibility and acceptability followed by effectiveness of bubble continuous positive airway pressure (CPAP) were not evaluated in childhood severe pneumonia in developing countries at a larger scale.
Objectives:
Stages I and II
* To assess the feasibility and acceptability (not only by patients' care-givers but also by physicians and nurses) of bubble CPAP in treating childhood severe pneumonia in two tertiary hospitals in Stage I and in two district hospitals in Stage II * To record adverse events following use of bubble CPAP in these settings * To understand how much resource and time are needed to institutionalize and maintain bubble CPAP as a routine practice in the health system
Stage III:
* To determine therapeutic efficacy/effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure in children admitted to hospitals with severe pneumonia and hypoxemia * To determine therapeutic effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure & mortality in children aged 1-12 months admitted to hospitals with severe pneumonia and hypoxemia * To record adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia) encountered.
Looking for future studies?
Notify Me1 month–59 month
All sexes
Interventional
Not applicable
Dhaka, Mohakhali, 1212, Bangladesh
Methodology:
Cluster randomized controlled clinical trial
Methodology:
a. Current treatment practice, facilities, and operational challenges will be evaluated for the introduction, clinical use and maintenance of bubble CPAP
Data collection-socio-demographic and clinical data will be collected using structured questionnaire by trained nurses and physicians.
Research Site:
St. Paulos Millennium Medical College, Yekatit 12 and Tikur Anbessa Specialized hospitals, 14 district hospitals
Number of Participants/Patients:
Stage I-30 children in each tertiary hospital (this stage has completed and we enrolled 49 children from two tertiary hospitals; these 49 enrolled children took double of our anticipated time {4 months}) Stage II- 20 children in each general hospital (2 general/district hospitals, we have enrolled total 40 children from this two hospitals from January 2020 to July 2020, which included COVID-19 period) Stage III-1240 children in 12 general/district hospitals (620 in bubble CPAP arm and 620 in WHO standard low flow arm; each hospital will be the cluster and 6 will be randomized to each arm)
Main Inclusion Criteria:
Statistical Analysis:
Study Duration:
48 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
To see the effectiveness of low flow oxygen in children with severe pneumonia
Time frame: 7 months
Patient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
According to this protocol treatment failure will be declared if the following criteria are met:
A. Presence of severe hypoxemia (SpO2<85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization
All will be measured in number and reported in percentage.
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
All will be measured in number and reported in percentage.
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
Length of hospital stay will be measured and reported in days.
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
Incidence of nasal trauma, gastric distention, shock and air leaks will be measured in number and reported in percentage.
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
Duration of bCPAP will be measured and reported in hour/hours.
Time frame: 12-18 months (Mid April 2021 to Mid October 2022)
Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage.
International Centre for Diarrhoeal Disease Research, Bangladesh
Other
Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03588377
Hypoxemia, Hypoxia
Jāmshoro, Sindh, Pakistan
View Trial DetailsNCT03831906
Actinomycetales Infections, Bacterial Infections
Kampong Cham, Cambodia
View Trial DetailsNCT07149909
Critical Illness, Cross Infection
Banhā, Benha, Egypt
View Trial DetailsNCT07112976
Infections, Lung Diseases
Milan, Italy
View Trial Details